|Cat. No. 218 011||
100 µg purified IgG, lyophilized. Albumin and azide were added for stabilization. For reconstitution add 100 µl H2O to get a 1mg/ml solution in PBS. Then aliquot and store at -20°C to -80°C until use.
Antibodies should be stored at +4°C when still lyophilized. Do not freeze!
Immunoprecipitation (IP); Immunoisolation or pulldown of a target molecule using an antibody. For details and product specific hints, please refer to the ”Remarks” section.', $event)" style="cursor: help;">IP: not tested yet
Immunocytochemistry (ICC) on 4% PFA fixed cells. Immunoreactivity is usually revealed by fluorescence. Some antibodies require special fixation methods. For details, please refer to the “Remarks” section.', $event)" style="cursor: help;">ICC: not tested yet
Immunohistochemistry (IHC) on 4% PFA perfusion fixed tissue with 24h PFA post fixation. Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate. Some antibodies require special fixation methods or antigen retrieval steps. For details, please refer to the ”Remarks” section.', $event)" style="cursor: help;">IHC: 1 : 400 (see remarks) gallery
Immunohistochemistry (IHC-P) of formalin fixed, paraffin embedded (FFPE) tissue (some antibodies require special antigen retrieval steps, please refer to the ”Remarks” section). Immunoreactivity is usually revealed by fluorescence or a chromogenic substrate.', $event)" style="cursor: help;">IHC-P: 1 : 100 gallery
Enzyme-linked immunosorbent assay (ELISA); a frequently employed method to quantify target-molecules in solution. The detection of some proteins requires special solubilization steps. For further information, please refer to the „Remarks“ section.', $event)" style="cursor: help;">ELISA: yes (see remarks)
|Subtype||IgG1 (κ light chain)|
|Immunogen||Synthetic peptide corresponding to AA 3 to 7 from human Abeta-pE3 (UniProt Id: P05067)|
Reacts with: human (P05067), rat (P08592), mouse (P12023), monkey.
Other species not tested yet.
|Specificity||Specific for Abeta-pE3.|
WB: Detects purified Abeta pE3. Complex samples like brain extracts still have to be tested.
Amyloid deposits, also called plaques, of Alzheimer's patients consist of several protein components like the amyloid beta-peptides (Abeta, Aβ) 1-40/42 and additional C- and N-terminally truncated and modified fragments. Very abundant are the isoaspartate (isoAsp)-Abeta and pyroglutamyl (pGlu)-Abeta peptides. The latter are formed by cyclization of the N-terminal glutamate at position 3 or 11 catalyzed by glutaminyl cyclase (QC) resulting in very amyloidogenic and neurotxic variants of Abeta; Abeta-pE3 and Abeta pE11.
In contrast to extracellular plaques that do not perfectly correlate with Alzheimer´s disease intraneuronal Abeta accumulation and vascular Abeta deposits have gained more and more evidence to be among the crucial factors responsible for progressive neuron loss.